Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $168000.0.

  • Champions Oncology's Cash from Financing Activities fell 2970.71% to $168000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $122000.0, marking a year-over-year decrease of 687.02%. This contributed to the annual value of $170000.0 for FY2025, which is 13225.81% up from last year.
  • Per Champions Oncology's latest filing, its Cash from Financing Activities stood at $168000.0 for Q4 2025, which was down 2970.71% from -$14000.0 recorded in Q3 2025.
  • Over the past 5 years, Champions Oncology's Cash from Financing Activities peaked at $239000.0 during Q4 2024, and registered a low of -$590000.0 during Q3 2023.
  • In the last 5 years, Champions Oncology's Cash from Financing Activities had a median value of $2000.0 in 2021 and averaged $1823.5.
  • Per our database at Business Quant, Champions Oncology's Cash from Financing Activities skyrocketed by 22142.86% in 2022 and then tumbled by 56875.0% in 2023.
  • Quarter analysis of 5 years shows Champions Oncology's Cash from Financing Activities stood at $121000.0 in 2021, then decreased by 28.93% to $86000.0 in 2022, then surged by 55.81% to $134000.0 in 2023, then soared by 78.36% to $239000.0 in 2024, then decreased by 29.71% to $168000.0 in 2025.
  • Its Cash from Financing Activities was $168000.0 in Q4 2025, compared to -$14000.0 in Q3 2025 and -$32000.0 in Q2 2025.